Background Despite therapeutic gains from immune checkpoint inhibitors (ICI) in many tumor types, new strategies are needed to extend treatment benefits, especially in patients failing to mount effective antitumor T-cell responses. Radiation and drug therapies can profoundly affect the tumor immune microenvironment. Here, we aimed to identify immunotherapies to increase the antitumor response conferred by combined ataxia telangiectasia and Rad3-related kinase inhibition and radiotherapy.
Methods Using the human papillomavirus (HPV)-negative murine oral squamous cell carcinoma model, MOC2, we assessed the nature of the antitumor response following ataxia telangiectasia and Rad3-related inhibitor (ATRi)/radiotherapy (RT) by performing RNA sequencing and detailed flow cytometry analyses in tumors. The benefit of immunotherapies based on T cell immunoreceptor with Ig and ITIM domains (TIGIT) and Programmed cell death protein 1 (PD-1) immune checkpoint blockade following ATRi/RT treatment was assessed in the MOC2 model and confirmed in another HPV-negative murine oral squamous cell carcinoma model called SCC7. Finally, immune profiling was performed by flow cytometry on blood samples in patients with head and neck squamous cell carcinoma enrolled in the PATRIOT clinical trial of combined ATRi/RT.
Results ATRi enhances radiotherapy-induced inflammation in the tumor microenvironment, with natural killer (NK) cells playing a central role in maximizing treatment efficacy. We demonstrated that antitumor activity of NK cells can be further boosted with ICI targeting TIGIT and PD-1. Analyses of clinical samples from patients receiving ATRi (ceralasertib) confirm the translational potential of our preclinical studies.
Conclusion This work delineates a previously unrecognized role for NK cells in the antitumor immune response to radiotherapy that can be augmented by small-molecule DNA damage–response inhibitors and immune checkpoint blockade.
- head and neck neoplasms
Data availability statement
Data are available upon reasonable request.
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Head and neck squamous cell carcinomas (HNSCCs) have an annual global incidence of approximately 750 000 cases with a mortality rate of around 50%.1 Classical risk factors are smoking, alcohol consumption, and human papillomavirus (HPV) infection. Surgery and/or radiotherapy/chemoradiotherapy are standard-of-care curative treatments in HNSCC. They are, however, associated with severe treatment-related morbidity and, in a significant proportion of patients, are ineffective at preventing locoregional recurrence and metastatic disease, which are the major causes of mortality.2 There is an urgent need for the development of effective, well-tolerated treatments that deliver durable locoregional and systemic disease control.
Radiotherapy induces the DNA damage response (DDR),3 which involves processes that sense DNA damage, induce cell cycle arrest, and attempt DNA repair to restore normal DNA sequence.4 Ataxia telangiectasia and Rad3-related (ATR) kinase is critical for replication fork stability in response to replication stress or radiation-induced DNA damage.5 Ataxia telangiectasia and Rad3-related inhibitors (ATRis) have shown promising clinical results as monotherapy particularly in tumors with ATM deficiency and have demonstrated radiosensitization in preclinical models.6–8
There is an emerging consensus that the DDR pathway defects or pharmacological inhibition can promote antitumor immune responses. Mechanistically, this is due to micronucleus generation, sensing of cytosolic DNA by cyclic GMP-AMP Synthase - Stimulator of Interferon Genes (cGAS-STING) and subsequent type I interferon (IFN) production.9 10 Our group and other groups have shown that combinations of radiation and AZD6738 reduce tumor burden and modulate the tumor immune microenvironment (TIME), with increased lymphocyte and myeloid cell infiltration in in vivo models.11 12 The efficacy of AZD6738, as monotherapy or combined with radiotherapy, is currently under clinical evaluation.13
Immune checkpoint inhibitors (ICIs) exert significant activity as single agents or in combination with cytotoxic chemotherapy in patients with relapsed/metastatic HNSCC.14–16 However, initial attempts to combine anti-programmed cell death protein 1 (PD-1) immune checkpoint inhibitors (ICI) and radiotherapy/chemoradiotherapy as curative treatments for locally advanced HNSCC have not delivered improvements on standard-of-care regimens.17 This failure may be due, at least in part, to the empirical, one-size-fits-all approach of simply adding anti-PD-1/anti-programmed death-ligand 1 (PD-L1) ICIs to current regimens, without any attempt at biomarker-led or mechanism-based patient selection. We posited that combining radiotherapy, DNA damage response inhibitors (DDRi) and ICIs might represent a rational approach to developing new therapeutic strategies derived from detailed preclinical analyses in relevant immunocompetent animal models.
Therefore, we have sought to understand how changes in tumor-infiltrating leukocytes that occur following radiation and AZD6738 combination therapy can be exploited to maximize therapeutic benefits. Here, using syngeneic mouse models of head and neck cancer, we confirm the profound impact of radiation and ATRi combination therapy on the TIME. We identify natural killer (NK) cells as critical players in mediating optimum treatment efficacy and show that their activity can be boosted with mechanistically appropriate ICI. In confirmatory studies, immune profiling of clinical samples supports the relevance of our findings to human cancers and points the way toward clinical translation.
Materials and methods
Blood samples were taken from patients enrolled on the phase I PATRIOT study of Cerralasertib (AZD6738) in combination with palliative radiotherapy (EudraCT: 2013-003994-84). Patients were 18 years and over, with a diagnosis of advanced solid malignancy and an indication for palliative radiotherapy. All patients had an Eastern Cooperative Oncology Group performance status of 0–2 with a life expectancy of at least 3 months and adequate organ function. Radiotherapy was administered daily, 2 Gy per fraction, Monday–Friday. A total of 30 Gy in 15 fractions was administered. Ceralasertib was administered orally at a dose of 80 mg (the recommended phase II dose), two times per day, for 3–7 days before the start of radiotherapy, during radiotherapy, and for 2 days after. Blood was taken before ceralasertib dosing, before fraction 1, before fraction 6, and before fraction 11, in an 8 mL EDTA tube and was processed within 24 hours of sampling.
Mouse models of head and neck cancer
Female C57BL/6 and C3H mice 8–14 weeks old were purchased from Charles River and allowed to acclimate to the Institute of Cancer Research (ICR) animal facility for a week. All animals were handled according to the Institute of Cancer Research and UK Home Office guidelines. In this study, we used three different models of murine immunocompetent HPV-negative head and neck cancer. The C57BL/6 mouse cancer cell line MOC2 was kindly provided by Ravindra Uppaluri (Dana-Farber Cancer Institute). The C3H mouse HPV-negative cancer cell lines AT-84 and SCC7 cells were kindly provided by Laird Forrest (University of Kansas) and Richard Vile (Mayo Clinic), respectively. Cells were cultured and maintained in Dulbecco Modified Eagle Serum supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin/streptomycin, and sodium pyruvate. Mice were inoculated subcutaneously on the right or left flank as indicated with 2×106 cells for both MOC2 or AT-84 models or 106 cells for the SCC7 model. Tumor growth was monitored every 3/4 days using a caliper and expressed as volume ((length×width×depth)/2). Mice were euthanized when tumors reached an average of 15 mm in two of the three dimensions.
In vivo tumor treatments
In vivo treatment was initiated when tumors reached an average of 50–200 mm3. The ATRi AZD6738 was provided by AstraZeneca and solubilized in 10% dimethyl sulfoxide (DMSO), 40% propylene glycol, 50% water, orally administrated 2 hours before irradiation for 5 or 7 consecutive days at 25 or 75 mg/kg/dose as indicated. Animal tumors were irradiated under anesthesia with Hypnorm and Hyprovel injected intraperitoneally. Irradiation was performed using an AGO 250 kV X-ray machine at a dose rate of 1.62 Gy/min (AGO). Animals were irradiated in the prone position and positioned under lead shielding with a 16 mm diameter aperture aligned over the tumor. A total of 8–24 Gy radiation dose in three to four fractions was given as indicated. Radiation dose was measured using a Farmer Chamberand Unidos-E Dosemeter (both PTW). When indicated, mice were treated with anti-TIGIT (clone 1G9) and/or anti-PD-1 (clone RMPD1-14) antibodies from BioXcell. Both antibodies were injected at a dose of 200 µg/mouse intraperitoneally, two times per week for 3 weeks, the first injection administrated just after the last radiation dose. For the depletion of NK cells, mice were injected intraperitoneally with 200 µg/mouse of anti-NK1.1 antibody (BioXcell, clone PK136) or 50 µL/mouse anti-Asialo-GM1 (BioLegend, clone Poly21450) into C57BL/6 mice or C3H mice, respectively, two times per week starting 1 day before treatment. For the depletion of CD8 T cells, mice were injected intraperitoneally with 200 µg/mouse of anti-CD8α (BioXcell, clone 2.43) two times per week starting 1 day before treatment.
Cytokine detection by ELISA
Tumors from MOC2- bearing mice were harvested 4 days after the last radiation dose and 1 day after the last ATRi dose. Tumors were weighted and collected in cold PBS until processing. Tumors were then homogenized in 1 mL PBS. Tubes were centrifuged and supernatants were collected for ELISAs. Detection of cytokines was performed using interferon gamma (IFN-γ), interferon beta (IFN-β) and interleukin (IL)-10 (R&D Systems) ELISA kits following the manufacturer’s instructions. Data were normalized with tumor weights.
RNA sequencing (RNA-seq)
MOC2 tumors were harvested 3 and 10 days after the last radiation dose. RNA from tumors was extracted and purified from tumors using the NucleoSpin RNA extraction kit (Macherey-Nagel). Library preparation and sequencing were performed by Genewiz (Leipzig, Germany). Library prep was strand-specific, used PolyA selection, with 2×150 bp sequencing at 10 million pairs performed on an Illumina NovaSeq. Quality control was performed using FastQC. Low-quality bases and adaptor sequences were removed using Trimmomatic. Reads were mapped to the Mus musculus GRCm38 reference genome using HISAT2, samtools and StringTie. Differential gene expression was assessed using DESeq2. Enrichment analysis for Gene Ontology terms was performed on differentially expressed genes (DEGs) using topGO. Active subnetwork-orientated gene set enrichment analysis using STRING protein–protein interaction networks and Kyoto Encyclopedia of Genes and Genomes pathways was performed using pathfindR. Immune cell composition was estimated from transcriptomic data using murine microenvironment cell population (mMCP)-counter. Data visualization used ggplot2 and ComplexHeatmap packages.
Flow cytometry analysis
Harvested tumors were excised, finely minced, and enzymatically digested for 30–45 min at 37°C in PBS containing 1 mg/mL collagenase type VI (Sigma-Aldrich), 1 mg/mL DNase type I (Roche), 100 ng/mL Dispase (Sigma-Aldrich), and trypsin. Digested tumors were smashed and filtered through a 70 μm pore cell strainer. Cells were centrifuged at 1400 rpm at 4°C for 10 min and pellets were washed in PBS/2% FCS/5 mM EDTA. Harvested spleen were mechanically dissociated, smashed, and filtered through a 70 μm pore cell strainer. Red blood cells were lysed by a 1 min incubation in ACK lysis buffer (Thermo Fisher Scientific). Cells were centrifuged at 1400 rpm at 4°C for 10 min and pellets were washed in PBS/2% FCS. For some experiments, mice were bled 20 µL from the tail vein. PBMCs from human blood samples were isolated on a density gradient medium (Lymphoprep, STEMCELL Technologies). Cells were incubated 4°C for 10 min with anti-mouse or anti-human CD16/CD32 (BD Pharmingen) prior to surface staining, 4°C for 30 min. The complete list of antibodies used in this study can be found in the online supplemental information. Intranuclear detection of Ki67 was performed using The Foxp3 Transcription Factor Staining Buffer Set (Thermo Fisher Scientific) following the manufacturer’s instructions. For intracellular cytokine detection and surface detection of CD107a, cells were incubated in complete IMDM containing Golgi Plug/Golgi Stop (BD Biosciences) in the presence of a stimulation cocktail containing PMA and ionomycin (Invitrogen) and mouse CD107a antibody for 4 hours at 37°C. Following surface antibody staining, cells were fixed using IC fixation buffer (Invitrogen), permeabilized in permeabilization buffer (Invitrogen), and stained with mouse IFN-γ antibody. Samples were analyzed on an LSR II or FACSymphony A5 (BD Biosciences), and flow cytometry (FACS) analyses were performed using the FlowJo V.10 software.
Statistical analysis were performed using GraphPad Prism software V.8 and V.9. Data are presented as means±SEM and are from a single or cumulative of two to three independent experiments. Areas under the curve were used to determine statistical differences in tumor growth between groups. Statistical differences between survival groups were determined using the log-rank Mantel-Cox test. Intensity of marker expression was shown as geometrical mean fluorescence intensity in the positive population. Unpaired t-test or one-way analysis of variance (ANOVA) followed by Tukey’s post t-test was used for statistical analysis when two or multiple groups were analyzed, respectively. When data did not follow a Gaussian distribution, we used non-parametric Mann-Whitney U or Kruskal-Wallis test followed by Dunn’s post-t-test for statistical analysis when two or multiple groups were analyzed, respectively. We used two-way ANOVA when multiple parameters were studied. Significant outliers were removed using the Grubb test. Statistical significance was assumed with *p<0.05, **p<0.005, ***p<0.001, and ****p<0.0001.
Combination of radiotherapy and ATR inhibition induce an antitumor response in head and neck cancer models
First, we evaluated the potential benefit of combining ATRi/RT in vivo using two murine oral squamous cell carcinoma models, MOC2 and AT84. Tumor-bearing mice were treated with conventionally fractionated RT, ATRi, or the combination (figure 1A).
MOC2 and AT84-bearing mice (figure 1B and online supplemental figure S1, respectively) displayed a marked reduction in tumor burden and significantly increased survival rates following ATRi/RT treatment when compared with control or single agents. To address whether an immune response was induced, we analyzed cytokine production in tumors following combination therapy. We observed a significant increase in IFN-β and IFN-γ production in response to ATRi/RT when compared with control (figure 1C). Interestingly, this was paralleled by a decrease in IL-10 production, which supports the induction of a strong proinflammatory response in the TIME (figure 1C).
Together, these data indicate a beneficial effect of ATRi in combination with RT in two different head and neck cancer models. Cytokine production analysis after the combination therapy also suggests the involvement of the immune system in this treatment effect.
ATRi and radiotherapy induce a gene expression profile characteristic of NK-cell activity
To determine the nature of the antitumor response following ATRi/RT, we performed RNA-seq in MOC2 tumors on days 3 and 10 postradiation. Principal component and differential gene expression analyses showed significant changes induced by ATRi and RT, with biological replicates clustering together (online supplemental figure S2). The number of DEGs was higher at day 3 in the combination therapy when compared with individual therapies (figure 2A). At day 10, a higher number of DEGs were observed for ATRi alone (figure 2A). Enrichment analysis for gene ontology terms linked to DEGs revealed the majority of treatment-induced changes appeared at day 3 (figure 2B, online supplemental table S1). Significant enrichment in all treatment groups was identified for the ontology terms response to bacterium, negative regulation of viral genome replication, cellular response to IFN-β, and defense response to virus (figure 2B), indicative of a viral mimicry signature. Enrichment for the ontology terms cytolysis, innate immune response, and stimulatory C-type lectin receptor signaling pathway was observed only in the ATRi/RT combination group (figure 2B). These ontology terms are rich in NK cell-associated transcripts. At day 10, most of the ontology groups mentioned at day 3 had returned to baseline except for cellular response to IFN-β and cytolysis in the case of ATRi/RT. As variations of gene expression were mostly detected at day 3, we focused on this timepoint in further analyses. Parallel pathway analysis of DEGs using the pathfindR package at day 3 showed significance for hepatitis C-associated, influenza A-associated, and measles-associated gene signatures in all groups when compared with control (figure 2C). These pathway terms are linked by IFN-stimulated genes (online supplemental table S2) that, again, reflect a viral mimicry signature. Strikingly, broad upregulation of a number of pathways was seen in response to ATRi/RT, including NK cell-mediated cytotoxicity, graft-versus-host disease, allograft rejection and type I diabetes mellitus (figure 2C). Therefore, gene ontology and pathfindR analyses both independently highlighted terms linked to NK-cell activity.
Immune cell population estimates highlighted the prominence of NK cells, monocytes, macrophages, and granulocytes (including eosinophils and neutrophils), but not CD8 T cells, in MOC2 tumors in response to ATRi/RT (figure 2D). In line with previous data, analyses of transcripts of individual genes revealed that the ATRi/RT combination significantly induced IFN signaling, chemoattractant and MHCI-related genes (figure 2E). In terms of immune cell population gene signatures, the most strikingly significant p values were observed for NK-cell receptors, such as Klrk1, Ncr1, and Klrg1 in response to ATRi/RT (figure 2F). We also detected, in the same treatment group, a marked increase in gene expression for immune cell activation markers, especially granzymes and perforin (figure 2G), which was sustained until day 10 post-treatment (online supplemental figure S3). Finally, consistent with an NK-cell gene signature, we found a marked increase in the expression of genes important for their activity, such as Il12b, Il15, Il15ra, and Il18 (online supplemental figure S4).
Taken together, RNA-seq analyses suggest that ATRi/RT combination therapy triggers a robust innate immune response likely to be mediated by the activity of NK cells.
ATRi and radiotherapy trigger an NK cell-mediated antitumor immune response
To confirm RNA-seq findings and define the cellular components of the immune system responsible for ATRi/RT-mediated antitumor activity, MOC2 tumors were analyzed with a focus on lymphocyte populations (gating strategy shown in online supplemental figure S5). We observed a decrease in the proportions of both CD4 and CD8 T cells in total immune cell infiltrates (live CD45+ cells) (figure 3A). The distribution of γδ and other T-cell populations was not affected. The combination of ATRi/RT enhanced the proportion of NK cells to a greater extent than single treatment regimens (figure 3A). The increased frequency of NK cells was even more pronounced when reported relative to the lymphocyte compartment (figure 3B). Studies on the myeloid cell compartment only showed significant variations in monocyte infiltrates (online supplemental figure S6).
Next, we determined the functional importance of NK cells to the therapeutic efficacy of ATRi/RT combination therapy. We compared MOC2 tumor growth in mice treated with ATRi/RT in the presence or absence of NK cells using specific depleting antibodies. While treatment efficacy was significantly decreased in the absence of NK cells (figure 3C), a similar experiment with a CD8-depleting antibody showed no involvement of CD8 T cells (figure 3D). This was despite efficient intratumoral depletion of both NK cells and CD8 T cells in tumors (online supplemental figure S7).
These data suggest that the accumulation of NK cells in the TIME plays a significant role in the efficacy of ATRi/RT combination therapy.
Combination of radiation and ATRi therapy increases NK-cell activation in the TIME
In line with data on the impact of NK-cell depletion, we investigated whether ATRi/RT administration induced an increase of the maturation/activation of NK cells in the TIME. We observed enhanced maturation of tumor-infiltrating NK cells as higher frequencies of CD11b+/CD27− cells on ATRi/RT treatment when compared with the control group (figure 3E). We noted a marked increase in the proportion of NK cells expressing activation/memory/proliferation markers, such as CD69, CD44, NKG2D, and Ki67, as well as the costimulatory molecule 4-1BB (figure 3F). We assessed whether the increased NK-cell activation detected in the tumor bed was accompanied by greater effector and killing capacities. Therefore, we analyzed intracellular IFN-γ staining and surface expression of the degranulation marker CD107a (LAMP-1) in intratumoral NK cells on ex vivo stimulation. We observed that radiotherapy and ATRi combination therapy strongly increased the frequencies of both IFN-γ and CD107a-positive NK cells (figure 3G).
Taken together, these results demonstrate that ATRi/RT combined treatment significantly boosts the activity of NK cells in the TIME, making them an interesting target for immunotherapies.
ATRi and radiation create a TIME suitable for modulation by immune checkpoint blockade
Next, we aimed to identify therapeutic strategies to increase the antitumor response conferred by ATRi/RT treatment. We hypothesized that immune checkpoint blockade could further boost the activity of NK cells in the TIME.
Thus, we addressed whether ATRi/RT increased or curbed surface expression of various immune checkpoint molecules on tumor-infiltrating NK cells. Although RNA-seq showed a significant decrease in its total gene expression (figure 2F), our results revealed that, among the various immune checkpoints studied, expression of TIGIT alone was enhanced on the surface of intratumoral NK cells after ATRi/radiation treatment when compared with control (figure 4A). Of note, TIGIT expression on the surface of CD4 T cells was slightly reduced and no variation was detected on CD8 T cells (online supplemental figure S8). We also observed a decrease in the frequencies of both PD-1 and CTLA-4-positive NK cells, whereas the frequencies of those expressing TIM-3, LAG-3, NKG2A, CD96 (tactile), or KLRG1 were unchanged (figure 4A). Interestingly, among the total TIGIT+ NK-cell population, matured CD11b+/CD27− NK cells were dominant (figure 4B).
Concerning the expression of immune checkpoint ligands in tumors, we detected higher proportions of cancer and myeloid cells (macrophages and monocytes) expressing one of the TIGIT ligands, namely, poliovirus receptor (PVR/CD155) (figure 4C). This provided further assurance that the TIGIT/PVR axis could serve as a relevant therapeutic target. Immune checkpoint antagonists, such as PD-1/PD-L1 antibodies, are approved to treat patients with head and neck cancer.18 Therefore, although the proportion of PD-1-positive NK cells declined in the TIME on treatment, we tested whether PD-L1 expression would follow an opposite trend and provide a rationale for using anti-PD-1/PD-L1 axis-blocking agents to improve ATRi/RT in MOC2 tumor-bearing mice. We noted a striking increase in PD-L1 expression on cancer cells and intratumoral myeloid cells in response to combination therapy (figure 4D).
Collectively, these results provide the rationale to combine TIGIT and/or PD-1-blocking antibodies with ATRi/RT treatment in order to unleash NK-cell activity in the TIME.
Combined blockade of TIGIT and PD-1 improves ATRi/RT-mediated tumor control
MOC2 tumor-bearing mice were treated with anti-TIGIT and/or anti-PD-1-blocking antibodies in addition to ATRi/RT. Systemic administration of anti-TIGIT and PD-1 antibodies significantly improved ATRi/RT treatment in terms of both tumor growth and tumor-specific survival (figure 5A). The concomitant combination of both anti-TIGIT and anti-PD-1 was necessary, as single antibody treatment failed to exert additional benefits to ATRi/RT.
Next, we checked whether favorable effects from TIGIT/PD-1 immunotherapy resulted in enhanced NK-cell activity in the TIME. To that end, we compared the effector capacity of tumor NK cells between ATRi/RT and ATRi/RT/anti-TIGIT/anti-PD-1 interventions. NK cells from ATRi/RT/anti-TIGIT/anti-PD-1-treated animals displayed enhanced intensity of CD44, IFN-γ, and CD107a expression ex vivo when compared with ATRi/RT treatment only (figure 5B).
We were interested to assess whether increasing the dose of both radiation and ATRi would further increase the effect of immunotherapy. Using this strategy, mice treated with the ATRi/RT/anti-TIGIT/anti-PD-1 displayed a more pronounced delay in tumor progression when compared with ATRi/RT alone (figure 5C). The efficacy of this treatment regimen was significantly reduced by the depletion of NK cells (figure 5C), indicating the critical contribution of NK cells to therapeutic efficacy. In order to expand the impact of our findings, we tested the same combination treatment in another syngeneic model, namely, SCC7. ATRi/RT treatment induced clear benefits in SCC7 tumor-bearing mice (figure 5D) when immunotherapy alone did not (online supplemental figure S9). Strikingly, all animals in the ATRi/RT/anti-TIGIT/anti-PD-1 combination therapy group achieved complete remission. This can be explained by the increased frequency of tumour-infiltrating CD8 T cells following RT in the SCC7 model when compared with MOC2 (online supplemental figure S10). Tumor control was not achieved in the absence of NK cells (figure 5D and online supplemental figure S11).
Together, these results indicate that the antitumor activity of NK cells can be further enhanced following ATRi/RT by immunotherapies based on TIGIT and PD-1 immune checkpoint blockade.
Combination of radiation and ATRi therapy boosts NK-cell activity in patients with HNSCC
In parallel with our mouse studies, we performed immune profiling on blood samples in patients with HNSCC enrolled in the PATRIOT clinical trial.13 As shown in the protocol (online supplemental figure S12), we collected samples at four different timepoints, allowing monitoring of the effect of radiation and ATRi (AZD6738) on NK-cell proportions and activation during treatment. We observed no clear modulation of the frequency of NK cells following therapy (figure 6A). In terms of activation, we noticed a progressive fold change increase in the proportions of 4-1BB and CD95-positive NK cells (figure 6B). The same trend was observed for the marker CD69, although the increase of expression was not sustained toward the end of the treatment (figure 6B). Interestingly, proportions of TIGIT-positive NK cells significantly increased in patients between baseline and prefraction 11 (figure 6C,D). In contrast, expression of PD-1-on NK cells was only increased in one patient and unchanged or decreased for the others (figure 6C).
Taken together, these data indicate that ATRi/RT enhanced NK-cell activation in patients with HNSCC. Furthermore, increased TIGIT expression on NK cells following treatment suggests that therapeutic interventions based on the inhibition of TIGIT signaling might also represent an interesting clinical strategy in humans to boost NK-cell activity following radiotherapy or ATRi/RT combination treatment.
The clinical development of PD-1/PD-L1 ICIs has transformed the management of patients with relapsed/metastatic head and neck cancer. As yet, attempts to introduce ICI earlier in the patient’s treatment journey, as part of curative-intent radiotherapy/chemoradiotherapy, have not been successful.14–16 Through syngeneic mouse models and analysis of clinical samples, this study points toward a means of combining radiation, ATR-targeted DDR inhibition, and immunotherapy to improve response and cure rates for patients with head and neck cancer by harnessing NK-cell activity.
A substantial body of research supports radiotherapy and ICIs as a promising therapeutic combination aimed at boosting antitumor immunity.10 19–24 The optimal dose, fractionation, and ICI combination regimen to maximize the immunogenic ‘viral mimicry’ response to radiotherapy remains an active area of investigation.22 25 This study, building on previous publications,8 11 supports the addition of ATR inhibition as a mechanism to enhance the immunogenicity of radiotherapy.
The ATRi ceralasertib in combination with radiotherapy has progressed from phase I13 and is now entering a phase II clinical trial in patients with HNSCC undergoing radical radiotherapy (EudraCT# 2020-001034-35). There is an emerging consensus that DDR defects, or the biological effects of DDRi agents are inextricably linked with type-I IFN signaling.10 11 26 27 Inhibition of DDR pathways increases micronucleus formation8 and levels of cytosolic DNA that drives type I IFN signaling in the TIME through activation of tumor cell cGAS or uptake of DNA by dendritic cells.10 28 29 Recent preclinical studies have identified the ability of DDRi agents alone, or paired with radiotherapy, to increase the efficacy of ICIs.30–32
The TIME comprises many different immune cells that exert antitumorous or protumorous functions.33 Research on radiotherapy and ICI combinations has focused almost exclusively on CD8 T and dendritic cells. Studies of ICIs alone show intratumoral CD8 T cells are associated with a favorable prognosis,34 35 with preclinical studies indicating the importance of CD8 T cells to the efficacy of radiation and DDRi combinations.12 36 37 Initial data in the MOC2 model indicated a radiotherapy-induced inflammatory response enhanced by ATRi that was associated with NK cells rather than CD8 T cells. To our knowledge, no previous study has shown the ability of ICIs to harness NK-cell activity in response to radiotherapy/DDRi combination. Therefore, we focused on the therapeutic role of NK cells postradiotherapy/ATRi.
Depletion experiments indicated NK cells were critical for the full efficacy of ATRi/RT. However, as NKT cells also express NK1.1, and NK cells are members of the innate lymphoid cell family, we cannot exclude the involvement of NKT cells or ILC1 cells. Increased NK-cell frequencies in MOC2 tumors by ATRi/RT were associated with enhanced maturation, activating receptor expression, cytokine production, and cytotoxic capacity, mirroring changes in CD8 T cells in analogous therapeutic settings.12 36 We were encouraged that many of the phenotypical changes in NK cells presented opportunities to exploit therapeutic approaches currently being developed preclinically and clinically.38
The ability of NK cells to kill tumor cells without prior antigen sensitization makes them attractive targets for immunotherapies,38 and we wished to exploit the vigorous NK-cell activity detected in the TIME following ATRi/RT treatment. It is probable that for some patients, particularly those with low mutational burdens or loss of neoantigen presentation, an efficacious antitumor T-cell response may not be possible. For these patients, harnessing antitumor NK-cell activity is a potential means to widen response rates to ICIs. Radiation-induced PD-L1 expression was greatly enhanced in the TME by the addition of ATRi/RT. This is in keeping with the emerging consensus that DDRi agents (or DDR defects) drive type I IFN signaling and, subsequently, PD-L1 expression.10 11 26 27 Despite this high PD-L1 signal, anti-PD-1 antibodies alone did not augment the therapeutic efficacy of ATRi/RT. This diversity of responses to anti-PD-1 immunotherapy between mouse models reflects the conclusions from clinical investigations, where overall response rates in patients are still low and intensive research is focused on alternative ICI approaches.
One such approach is dual-ICI blockade. Among all the immune checkpoints investigated in our study, only TIGIT showed enhanced surface expression on NK cells in response to ATRi/RT. TIGIT upregulation was most evident on mature CD11b+/CD27− NK cells. The TIGIT ligand, PVR (CD155), was also increased on cancer cells, monocytes and macrophages. Interestingly, TIGIT was not flagged as a target of interest in our global RNA-seq analysis, which showed a significant decrease of total Tigit transcripts in MOC2 tumors. Flow cytometric data indicated stable surface TIGIT expression in CD8 T cells and reduced expression in CD4 T cells, contrasting with elevation on NK cells.
A number of anti-TIGIT antibodies are under clinical evaluation in patients with cancer.39 Interference with TIGIT signaling in NK cells has recently been shown to be particularly relevant for antitumor immunity.40 41 Having said that, in MOC2-bearing mice treated with ATRi/RT, TIGIT blockade alone, like PD-1 blockade alone, was insufficient to enhance therapeutic outcomes. Recent investigations have highlighted the potential of targeting TIGIT, with or as an alternative to PD-1 axis blockade.42 43 Grapin and colleagues reported that only dual anti-PD-1 and anti-TIGIT blockade was effective in delivering additional antitumor control in combination with radiotherapy in the CT-26 model.44 In our study, the prominent expression of PD-L1 observed on cancer and myeloid cells following ATRi/RT provided a strong rationale for blockade of the PD-1/PD-L1 axis, with PVR expression and the NK cell-specific levels of TIGIT providing a strong rationale for concomitant blockade of the TIGIT signaling axis. Subsequently, dual PD-1/TIGIT blockade was confirmed to enhance NK cell-mediated tumor control in combination with ATRi/RT. Considering levels of surface expression of both PVR and PD-L1 on cancer and myeloid cells following ATRi/RT, the effect of combined TIGIT and PD-1 blockade is likely due to the disruption of the binding of those receptors to their ligands, PVR, and PD-L1. However, we cannot rule out the possibility that other TIGIT and PD-1 ligands, such as Nectin-2 and PD-L2, play a role in the effects we observed.
NK-cell activity can be associated with a positive prognosis in patients with human cancer,45 46 particularly in HNSCC.2 Analysis of clinical samples from patients receiving radiation and ATRi treatment indicated an increase in NK-cell surface expression of activation markers after combined ATRi/RT, in line with our preclinical data. Of note, the presence of mature CD56dim NK cells, a subpopulation with increased cytolytic activities,47 was correlated with improved survival in patients with with HNSCC.2 We found that TIGIT was generally highly expressed on blood NK cells, which has been reported previously in patients with HNSCC.40 TIGIT signaling impairs human NK-cell cytotoxicity toward tumor cells.48 Due to increased frequencies of NK cells expressing TIGIT following combined ATRi/RT, it is tempting to hypothesize that those patients might derive therapeutic benefit from additional treatments based on anti-TIGIT and/or anti-PD-1-blocking antibodies.
To conclude, our study has demonstrated the potential to exploit NK-cell activity to improve radiation and DDRi therapeutic effects in head and neck cancer. This approach has the potential to be translated to clinical studies, with particular relevance to poorly immunogenic tumors. Such a strategy might provide an attractive alternative to traditional T cell-based approaches, with the potential to expand the number of patients responsive to cancer immunotherapy in the near future.
Data availability statement
Data are available upon reasonable request.
Patient consent for publication
This study involves human subjects and was approved by NRES Committee London – City and EastREC (ref: 14/LO/0465), and was conducted in accordance with protocol requirements, Good Clinical Practice, and the guiding principles of the Declaration of Helsinki. All subjects provided written informed consent to participate in the study before taking part. The protocol was reviewed by the local ethics committee.
Contributors ECP, KJH, MM, and MTD contributed to the conception and design of the research as well as in writing the manuscript; ECP, MM, MTD, LG, GB, EC-R, HB, HW, GB, and JK performed the experiments and acquired data; ECP, KJH, MM, MTD, MP, PN, JH, HG, SS, and AAM contributed to the analysis and interpretation of the data. MM and PN provided support for bioinformatics analysis; MTD, PN, HS, IL, DN, and JG contributed to the collection and supply of clinical samples. JH, HG, and SS contributed to the supply of reagents. KJH is the guarantor, senior author and provided funding for the project. All authors read and approved the final manuscript.
Funding This study was supported by RM/ICR NIHR Biomedical Research CentreCenter (KH), Rosetrees Trust (EP, MD, and KH; grant numbers M48 and M444), Cancer Research United Kingdom (MD, AM, and KH) and The Oracle Cancer Trust (EP, MM, MP, EC-R, and KH).
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.